We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
101
Collegium Pharmaceutical
COLL
$1.15B
$1.22M 0.02%
31,696
+18,400
+138% +$656K
MMM icon
102
3M
MMM
$91.9B
$1.21M 0.02%
+8,875
New +$1.09M
LEA icon
103
Lear
LEA
$7.26B
$1.21M 0.02%
11,067
+5,510
+99% +$626K
DHIL
104
DELISTED
Diamond Hill
DHIL
$1.2M 0.02%
+7,404
New +$1.14M
NVAX icon
105
Novavax
NVAX
$1.23B
$1.17M 0.02%
+92,597
New +$1.2M
LTH icon
106
Life Time Group Holdings
LTH
$9.74B
$1.16M 0.02%
47,343
+14,411
+44% +$324K
MATV icon
107
Mativ Holdings
MATV
$455M
$1.16M 0.02%
68,020
+49,143
+260% +$863K
ARCB icon
108
ArcBest
ARCB
$3.31B
$1.15M 0.02%
+10,614
New +$1.17M
MNKD icon
109
MannKind Corp
MNKD
$1.22B
$1.15M 0.02%
182,776
-13,801
-7% -$79.3K
AMPL icon
110
Amplitude
AMPL
$1.15B
$1.14M 0.02%
+127,474
New +$1.09M
SAM icon
111
Boston Beer
SAM
$1.91B
$1.12M 0.02%
+3,876
New +$1.08M
ACHC icon
112
Acadia Healthcare
ACHC
$2.99B
$1.12M 0.02%
+17,673
New +$1.28M
DT icon
113
Dynatrace
DT
$12.7B
$1.11M 0.02%
+20,722
New +$987K
HTO
114
H2O America
HTO
$2.66B
$1.1M 0.02%
+19,014
New +$1.11M
TOI icon
115
The Oncology Institute
TOI
$519M
$1.1M 0.02%
3,360,052
– –
TT icon
116
Trane Technologies
TT
$107B
$1.09M 0.02%
+2,799
New +$971K
HNRG icon
117
Hallador Energy
HNRG
$717M
$1.06M 0.02%
112,711
+71,819
+176% +$511K
TWST icon
118
Twist Bioscience
TWST
$5.39B
$1.06M 0.02%
23,424
+3,968
+20% +$189K
ED icon
119
Consolidated Edison
ED
$41.1B
$1.05M 0.02%
+10,098
New +$999K
JCI icon
120
Johnson Controls International
JCI
$87.5B
$1.05M 0.02%
+13,530
New +$949K
SCS
121
DELISTED
Steelcase
SCS
$1.05M 0.02%
+77,692
New +$1.04M
CNXC icon
122
Concentrix
CNXC
$1.5B
$1.05M 0.02%
20,438
+11,654
+133% +$780K
HCKT icon
123
Hackett Group
HCKT
$255M
$1.04M 0.02%
+39,550
New +$992K
PLAB icon
124
Photronics
PLAB
$1.76B
$1.04M 0.02%
+41,813
New +$1.01M
VEEV icon
125
Veeva Systems
VEEV
$31.6B
$1.02M 0.02%
4,854
+562
+13% +$111K
3 4
5
6 7

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.